US FDA cancels panel review for Ovation's Sabril
This article was originally published in Scrip
The US FDAhas cancelled the August 6th-7th advisory panel review of Ovation's epilepsy drug Sabril (vigabatrin) because of difficulties empanelling the necessary experts owing to scheduling problems and conflicts of interest. The peripheral and central nervous system drugs panel was to consider the use of vigabatrin in two indications under priority review – adjunctive therapy for refractory partial seizures in adults and infantile spasms. Ovation previously said it anticipates receiving an action letter by the end of August and a final decision in the fourth quarter.
You may also be interested in...
Agency wants to ensure patients ‘aren’t unnecessarily or unfairly scared off or intimidated’ from taking biosimilars, Office of Therapeutic Biologics and Biosimilars' acting policy director Eva Temkin tells the FDA/CMS Summit; Temkin says recent guidance on biosimilar insulins shows agency is trying to be flexible on interchangeability data requirements.
AstraZeneca and Merck seek to add a pancreatic cancer indication for olaparib, while Merck has hopes of broadening pembrolizumab’s use in bladder cancer; two-day Oncologic Drugs Advisory Committee meeting also will include reviews of Celgene’s luspatercept in myelodysplastic syndromes-related anemia and Epizyme’s tazemetostat for epithelioid sarcoma.
Clinicians and sponsors want the US FDA to open up antibacterial labeling to include more data on efficacy against resistant pathogens and in other body sites, but regulatory restrictions may require a workaround in the form of rapid, peer-to-peer communications about the data on new products.